BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 11763165)

  • 1. The Hsp90 chaperone as a promising drug target.
    Piper PW
    Curr Opin Investig Drugs; 2001 Nov; 2(11):1606-10. PubMed ID: 11763165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer.
    Moser C; Lang SA; Stoeltzing O
    Anticancer Res; 2009 Jun; 29(6):2031-42. PubMed ID: 19528462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stability of the Peutz-Jeghers syndrome kinase LKB1 requires its binding to the molecular chaperones Hsp90/Cdc37.
    Nony P; Gaude H; Rossel M; Fournier L; Rouault JP; Billaud M
    Oncogene; 2003 Dec; 22(57):9165-75. PubMed ID: 14668798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FK228 inhibits Hsp90 chaperone function in K562 cells via hyperacetylation of Hsp70.
    Wang Y; Wang SY; Zhang XH; Zhao M; Hou CM; Xu YJ; Du ZY; Yu XD
    Biochem Biophys Res Commun; 2007 May; 356(4):998-1003. PubMed ID: 17397803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Hsp90 for the treatment of cancer.
    Drysdale MJ; Brough PA; Massey A; Jensen MR; Schoepfer J
    Curr Opin Drug Discov Devel; 2006 Jul; 9(4):483-95. PubMed ID: 16889231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthetic ansamycins prepared by a ring-expanding Claisen rearrangement. Synthesis and biological evaluation of ring and conformational analogues of the Hsp90 molecular chaperone inhibitor geldanamycin.
    McErlean CS; Proisy N; Davis CJ; Boland NA; Sharp SY; Boxall K; Slawin AM; Workman P; Moody CJ
    Org Biomol Chem; 2007 Feb; 5(3):531-46. PubMed ID: 17252137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress.
    Workman P; Burrows F; Neckers L; Rosen N
    Ann N Y Acad Sci; 2007 Oct; 1113():202-16. PubMed ID: 17513464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
    Powers MV; Workman P
    Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S125-35. PubMed ID: 17259553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ATPase inhibitors of heat-shock protein 90, second season.
    Janin YL
    Drug Discov Today; 2010 May; 15(9-10):342-53. PubMed ID: 20230904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis.
    Tsutsumi S; Neckers L
    Cancer Sci; 2007 Oct; 98(10):1536-9. PubMed ID: 17645779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heat shock protein 90: a unique chemotherapeutic target.
    Cullinan SB; Whitesell L
    Semin Oncol; 2006 Aug; 33(4):457-65. PubMed ID: 16890800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined pharmacophore and structure-guided studies to identify diverse HSP90 inhibitors.
    Sanam R; Tajne S; Gundla R; Vadivelan S; Machiraju PK; Dayam R; Narasu L; Jagarlapudi S; Neamati N
    J Mol Graph Model; 2010 Feb; 28(6):472-7. PubMed ID: 20005756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Heat shock protein 90: novel target for cancer therapy].
    Chen Y; Ding J
    Ai Zheng; 2004 Aug; 23(8):968-74. PubMed ID: 15301726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heat-shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010.
    Messaoudi S; Peyrat JF; Brion JD; Alami M
    Expert Opin Ther Pat; 2011 Oct; 21(10):1501-42. PubMed ID: 21689065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
    Workman P
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.
    Beliakoff J; Bagatell R; Paine-Murrieta G; Taylor CW; Lykkesfeldt AE; Whitesell L
    Clin Cancer Res; 2003 Oct; 9(13):4961-71. PubMed ID: 14581371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of benzisoxazoles as potent inhibitors of chaperone heat shock protein 90.
    Gopalsamy A; Shi M; Golas J; Vogan E; Jacob J; Johnson M; Lee F; Nilakantan R; Petersen R; Svenson K; Chopra R; Tam MS; Wen Y; Ellingboe J; Arndt K; Boschelli F
    J Med Chem; 2008 Feb; 51(3):373-5. PubMed ID: 18197612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hsp90--a target for anticancer therapy].
    Růcková E; Müller P; Vojtesek B
    Klin Onkol; 2011; 24(5):329-37. PubMed ID: 22070013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hsp90: a chaperone for protein folding and gene regulation.
    Zhao R; Houry WA
    Biochem Cell Biol; 2005 Dec; 83(6):703-10. PubMed ID: 16333321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity.
    Rowlands MG; Newbatt YM; Prodromou C; Pearl LH; Workman P; Aherne W
    Anal Biochem; 2004 Apr; 327(2):176-83. PubMed ID: 15051534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.